6 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 9 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow RVX000222: new trials by email Literature Review of RVX000222 trials Research Report on RVX000222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Apabetalone in Subjects With Long -COVID Apabetalone - Post-Acute COVID-19 Syndrome | Phase 2 / Phase 3 | Recruiting | Resverlogix Corp | 200 | 2025-04-15 | 2025-04-18 |
| A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis apabetalone, Placebos - Kidney Failure, Chronic | Phase 1 / Phase 2 | Not yet recruiting | Resverlogix Corp | 44 | 2024-11-22 | 2023-11-15 |
| Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease RVX000222 - Fabry Disease | Phase 1 / Phase 2 | Withdrawn | Resverlogix Corp | 2022-11-22 | 2023-11-18 | |
| Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD Apabetalone, Placebo, Atorvastatin - Diabetes Mellitus, Type 2, Coronary Artery Disease | Phase 3 | Completed | Resverlogix Corp | 2425 | 2015-11-01 | 2021-08-20 |
| Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia RVX000222, Rosuvastatin, Atorvastatin - Dyslipidemia, Coronary Artery Disease | Phase 2 | Terminated | Resverlogix Corp | 13 | 2013-05-01 | 2015-05-12 |
| The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes RVX000222, Placebo, RVX000222 - Diabetes | Phase 2 | Completed | Resverlogix Corp | 20 | 2012-11-01 | 2014-04-02 |
| ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation RVX000222, Placebo RVX000222 - Coronary Artery Disease | Phase 2 | Completed | Resverlogix Corp | 324 | 2011-09-01 | 2013-06-04 |
| The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation RVX000222, Placebo RVX000222 - Coronary Artery Disease, Dyslipidemia | Phase 2 | Completed | Resverlogix Corp | 176 | 2011-08-01 | 2012-09-20 |
| Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease RVX000222, Placebo - Atherosclerosis, Coronary Artery Disease | Phase 2 | Completed | Resverlogix Corp | 299 | 2009-12-01 | 2023-04-03 |
| Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol RVX000222, Placebo - Dyslipidemia, Atherosclerosis | Phase 1 / Phase 2 | Completed | Resverlogix Corp | 72 | 2008-09-01 | 2022-11-04 |
Coronary Artery Disease (5) · Atherosclerosis (4) · Dyslipidemias (3) · Cardiovascular Diseases (2) · Acute Coronary Syndrome (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Fabry Disease (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Post-Acute COVID-19 Syndrome (1)
Resverlogix Corp (10)
Australia (3) · Argentina (2) · Belgium (2) · Hungary (2) · Netherlands (2) · Poland (2) · Russia (2) · United States (2) · Brazil (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Germany (1) · Israel (1) · Jordan (1)
Allan Gordon, MD, PhD (1) · Dr. Sepehr Shakib (1) · Dr. Stephen Duffy (1) · Kausik Ray, MD (1) · Michael Sweeney, MD (1) · Michael West, MD (1) · Professor Bronwyn Kingwell (1) · Stephen Nicholls, MBBS, PhD (1) · Steve Nicholls, MBBS, PhD (1) · Steve Nicholls, MD, PhD (1)
PMID 21255957, PMID 22349989, PMID 26385396, PMID 30476723, PMID 31520897, PMID 31725015, PMID 32219359, PMID 34158057